ClinicalTrials.Veeva

Menu

Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency

The University of Chicago logo

The University of Chicago

Status

Completed

Conditions

Adrenal Insufficiency

Study type

Observational

Funder types

Other

Identifiers

NCT03000231
14-1484

Details and patient eligibility

About

The purpose of this study is to compare cardio-metabolic risk, glucose tolerance, and night time blood pressure between healthy control subjects and patients with adrenal insufficiency. No intervention will be administered and the study is observational only.

Full description

We propose to use a case control design to test the main hypothesis that as compared to healthy control subjects matched for sex, age, adiposity and race/ethnicity, patients with adrenal insufficiency, whether primary or secondary, have disturbances of the circadian system that are associated with high day to day variability of sleep time as well as elevated markers of cardio-metabolic risk, including abnormal oral glucose tolerance and reduced nocturnal blood pressure dipping.

A secondary hypothesis of the study is that adrenal insufficiency patients on a replacement regimen (as part of their standard of care ongoing treatment) that results in daytime cortisol profiles approximating the normal diurnal variation will have better cardio-metabolic function than adrenal insufficiency patients who have grossly abnormal cortisol profiles.

Enrollment

86 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Primary or secondary adrenal insufficiency, Healthy matched controls, acute or unstable health conditions age 18 or older

Exclusion criteria

  • Diabetes, Tertiary adrenal insufficiency

Trial design

86 participants in 2 patient groups

Healthy Controls
Description:
Matched by age, race, gender and BMI to adrenal insufficiency subjects
Adrenal Insufficiency Patients
Description:
Eligible patients will have either primary adrenal insufficiency or secondary adrenal insufficiency and will be age 18 and older.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems